Dosage
The recommended starting dosage of Tirzepatide is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.
After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.
If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
The maximum dosage of Tirzepatide is 15 mg injected subcutaneously once weekly.
If a dose is missed, instruct patients to administer Tirzepatide as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).
Important Administration Instructions
Prior to initiation, train patients and caregivers on proper injection technique.
Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL dose).
Administer Tirzepatide once weekly, any time of day, with or without meals.
Inject Tirzepatide subcutaneously in the abdomen, thigh, or upper arm.
Rotate injection sites with each dose.
Inspect Tirzepatide visually before use. It should appear clear and colorless to slightly yellow. Do not use Tirzepatide if particulate matter or discoloration is seen.
When using Tirzepatide with insulin, administer as separate injections and never mix. It is acceptable to inject Tirzepatide and insulin in the same body region, but the injections should not be adjacent to each other.
Reviews
There are no reviews yet.